Q-omics provides the consensus-scored ABHD12B profile across patient tissues and cancer cell-line models. ABHD12B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ABHD12B is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, ABHD12B RNA expression shows 15,514 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, KICH, and KIRP as cancer lineages where ABHD12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD12B survival associations across molecular data types. ABHD12B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD12B RNA expression–survival associations across cancer types. High ABHD12B expression shows unfavorable associations in COAD, HNSC and LGG, but favorable associations in UCEC, MESO and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify COAD as the clearest survival context for ABHD12B RNA expression.
This table summarizes ABHD12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD12B shows lower tumor expression in KICH, LUAD and PRAD and higher tumor expression in KIRC, LIHC and HNSC. The KICH box plot shows higher ABHD12B RNA expression in normal versus tumor tissue (log2 FC = −0.370, t-test p < 0.001).
This table shows molecular features associated with ABHD12B in patient tissues and cancer cell lines. In patient samples, ABHD12B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
